Hims 2026: Reading the Growth Story Without the Marketing Slide

Unit-economics tells: follow the bridge, not the headline

Growth and mix

Consolidated revenue grew 38%, subscribers grew 19%, and U.S. revenue grew 16%. The mismatch is the investigative starting point—not proof that existing domestic customers suddenly became much more valuable. The release reports a higher Monthly Revenue per Average Subscriber and a much larger Rest-of-World business; management also points to an acquisition closed during the quarter. A memo should separate those contributors before describing “underlying” growth. Do not call the 19% subscriber increase a U.S. subscriber growth rate: it is the reported subscriber metric. Hims & Hers Q2 2026 financial results

Monthly Revenue per Average Subscriber is total revenue ÷ average subscribers ÷ months in the period; average subscribers is the average of beginning- and end-of-period counts. It is therefore a useful revenue-intensity measure, but not a clean same-customer spending measure. Revenue from outside the subscriber count, acquisition effects, and product mix can complicate interpretation. The $92 figure cannot be converted into customer lifetime value without retention, margin, and acquisition-cost evidence. Hims & Hers Q2 2026 financial results

Margin and cash

Gross margin fell from 76% to 64%. Management associates the pressure with branded weight-loss and international mix. Treat that as an explanation to test: what share of revenue came from each category, what are their respective margins, and how much of the mix shift is expected to persist? Compression is information, not automatically a failed model; equally, faster revenue growth does not make it immaterial. Hims & Hers Q2 2026 financial results

Do not substitute an Adjusted EBITDA story for the earnings and cash record. Q2 Adjusted EBITDA was about $60.3M, down from $82.2M; the quarter also recorded an approximately $86.3M net loss, versus net income a year earlier, and roughly negative $68.2M free cash flow. A memo needs the reconciliation and the cash-flow drivers, not a choice of whichever profit measure best fits its thesis. For customer-acquisition claims, calculate marketing expense as a share of revenue from a consistently defined expense line if available; that ratio is not CAC. CAC also requires attributable acquisition spend and a defensible new-customer denominator. Do not invent CAC, LTV, or payback from the figures above. Hims & Hers Q2 2026 financial results

Cohort versus vanity: what does “nearly 3 million” mean?

The company defines subscribers as customers with at least one auto-billed subscription; one-time purchasers are excluded. Its definition also permits cancellation or snoozing between billing periods. That makes the precise counting rule important, but does not establish that inactive accounts were included in the 2.891M period-end total. Ask how billing-cycle timing, pauses, reactivations, and cancellations affect the reported count before treating it as a continuously paying population. Hims & Hers Q2 2026 financial results

The evidence request is cohort-shaped: new versus continuing subscribers; retention by signup period and product category; pause and restart behavior; repeat purchasing outside subscriptions; and contribution after product, clinical, fulfillment, and acquisition costs. The release’s period-end count and average-subscriber revenue measure do not supply those curves. Write “retention not established by this release,” not “retention is strong” or “retention is weak.”

Narrative versus evidence pack

Management describes a doctor-led AI clinical engine, a domestic acceleration opportunity, international expansion, and 2030 targets of at least $6.5B in revenue and $1.3B in Adjusted EBITDA. These belong in a memo as management propositions. The reported quarter belongs in the evidence column: $753.2M revenue, 16% U.S. revenue growth, a larger Rest-of-World contribution, 64% gross margin, and the earnings and cash measures above. Neither column should be silently substituted for the other. Hims & Hers Q2 2026 financial results

For each proposition, specify its test. “Domestic acceleration” calls for successive U.S. growth readings and a mix-adjusted explanation. “International scale-up” calls for acquisition-versus-organic growth, integration costs, and regional contribution margins. “AI efficiency” calls for measurable changes in clinical workflow, service quality, and unit costs—not merely an AI description. Long-range targets require a bridge through subscriber cohorts, revenue intensity, gross margin, operating expense, and cash conversion. Mark missing bridges as limits, rather than filling them with assumptions presented as facts.

Regulatory and advertising risk: memo checklist

This is an operational diligence frame, not a legal opinion or a claim that a specific violation occurred. The company’s weight-loss mix discussion makes product and claims discipline material to how a reader assesses growth. Hims & Hers Q2 2026 financial results

• Claims inventory: What do ads and landing pages promise, and what evidence supports each clinical, price, and availability claim?
• “Access” language: Does it mean an evaluation, a prescription when clinically appropriate, product availability, or delivery? Are those distinctions clear?
• Product mix: Can the company distinguish branded from compounded offerings and explain how mix affects margin and operational exposure?
• Clinical process: What documents prescribing oversight, eligibility decisions, follow-up, and escalation across telehealth workflows?
• Channel controls: How are affiliate, influencer, and paid-search claims approved, monitored, corrected, and retained?
• Jurisdiction and change control: Who tracks applicable FDA, state-board, and FTC developments, and who can stop or revise a campaign?
• Memo evidence: Which disclosures, policies, and dated examples support the risk assessment? If unavailable, record the gap rather than implying clearance.

Hype versus load-bearing reading

These distinctions follow from the release’s reported metrics and definitions; the requested cohort and milestone evidence is not supplied by those headline measures. Hims & Hers Q2 2026 financial results

Client-memo file: minimum contents

Before circulating a conclusion, check that the file contains:

1. A dated fact table with period, units, year-on-year comparison, metric definitions, and a direct source link.
2. A growth bridge separating U.S., Rest-of-World, acquisition effects, subscriber growth, and revenue intensity—marking any allocation the release does not quantify.
3. An economics bridge covering gross-margin mix, marketing-spend definition if available, Adjusted EBITDA reconciliation, net result, and cash flow.
4. A cohort request list for retention, pauses, reactivations, CAC, and contribution by product and geography; label undisclosed items plainly.
5. A claims-and-risk log linking management’s AI, domestic, international, and 2030 statements to testable evidence and advertising controls.
6. A limits paragraph stating what the quarter cannot prove about durable demand or future profitability. Hims & Hers Q2 2026 financial results

Sources

• Hims & Hers Health, Inc., “Reports Second Quarter 2026 Financial Results”. Company investor release; source for reported figures, definitions, guidance, and attributed management statements in this file. Reading framed as of September 2026.

Put the method to work

Start free on mmarw.com to turn growth decks into a decision file. Plans: Free, Starter $6, and Professional $24.

This is not investment advice or a recommendation to buy or sell any security.